R&D Strategy

Developing new medicines is always a long and expensive process. Each treatment method and dosage form often requires organizing and even creating an R&D infrastructure from scratch. This ensures that the development of effective and safe medicines is of high quality and meets all regulatory requirements. Different classes of molecules require different expertise. Specialized knowledge makes the development process more efficient in terms of time and costs. Understanding the regulatory framework for different drug groups is also critical. Meeting all of these needs and requirements makes patients wait longer for the therapies they need now.

Maximizing the efficiency of R&D processes is a key factor in determining the cost of development and the time it takes for a drug to reach the patient. That is why it is one of our main strategic imperatives, priorities and even part of our R&D culture. We focus our efforts on maximizing it in several areas.

We recognize that diseases that are complex in nature and difficult to treat, as well as the problems of antibiotic resistance and aging, can only be solved through the collaboration of the most prominent representatives of science and healthcare. We are open to interaction and actively cooperate with colleagues from different fields at every stage of the R&D process – from idea to clinical development. Collaboration in basic research is of particular importance to us, as we believe that this is the only way to identify and discover completely new opportunities for treating the most complex diseases.